Development of molecular targeted therapy for patients with skin cancer

2015 Fiscal Year Final Research Report

• Project/Area Number: 25860979
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Dermatology
• Research Institution: National Cancer Center Japan
• Principal Investigator: Tanaka Ryota 国立研究開発法人国立がん研究センター, その他部局等, 研究員 (90649667)
• Research Collaborator: OMATA Wataru 国立がん研究センター中央病院, 皮膚腫瘍科, がん専門修練医 ; OASHI Kohei 国立がん研究センター中央病院, 皮膚腫瘍科, 任意研修医 (00640343) ; TSUTA Koji 関西医科大学, 病態検査学講座, 教授 (00392332) ; TSUDA Hitoshi 防衛医科大学校, 病理病態学, 教授 (70217321) ; YAMAZAKI Naoya 国立がん研究センター中央病院, 皮膚腫瘍科, 科長
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 乳房外パジェット病 / 分子標的治療 / HER2 / 皮膚悪性腫瘍

Outline of Final Research Achievements

THe study assessed the concordance of HER2 protein and gene status between primary and metastatic sites of extramammary Paget disease and evaluate whether they are suitable as target. Twenty-six metastatic sites of primary EMPD underwent evaluation . HER2 protein overexpression and gene amplification were detected in 38% and 19%, respectively. In 24 out of 26 cases (92%), there were no changes in HER2 status between the primary tumors and the corresponding lymph node metastasis (kappa coefficient 0.75). HER2 status was of good overall concordance between primary tumors and corresponding metastatic sites, suggesting there should be adaptation for HER2 targeted therapy in patients with HER2 positive EMPD.

Free Research Field

内科系臨床医学